Foresee Pharmaceuticals Co., Ltd., a clinical-stage biopharmaceutical company, engages in the development and commercialization of drugs in Taiwan and internationally.
The last earnings update was 6 days ago.
Discounted Cash Flow Calculation for GTSM:6576 using 2 Stage Free Cash Flow to Equity Model
The calculations below outline how an intrinsic value for
is arrived at by discounting future cash flows to their present value using the 2 stage method.
We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.
Note: Free cash flow to equity valuations ignore the company's cash or debt.
GTSM:6576 DCF 1st Stage: Next 10 year cash flow forecast
Amount off the current price
is available for.
Share price is
vs Future cash flow value of
Current Discount Checks
to be considered undervalued it must be available for at least 20% below the
current price. Less than 40% is even better.
Foresee Pharmaceuticals's share price is below the future cash flow value, and at a moderate discount (> 20%).
Foresee Pharmaceuticals's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Foresee Pharmaceuticals's earnings available for a low price, and how does
this compare to other companies in the same industry?
Foresee Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.
Foresee Pharmaceuticals's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Foresee Pharmaceuticals's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Foresee Pharmaceuticals's finances.
The net worth of a company is the difference between its assets and liabilities.
Foresee Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Foresee Pharmaceuticals's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
Foresee Pharmaceuticals's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Debt is covered by short term assets, assets are 3.1089023767682E+17x debt.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Lawrence Gan, Ph.D., has been the Chief Executive Officer of Foresee Pharmaceuticals Co., Ltd. since August 1, 2017 and serves as its President. Dr. Gan leads Foresee's global strategy including portfolio planning, technology and platform research, preclinical and clinical development, commercialization, M&A and capital market activities. Dr. Gan has 30-year strategic and operational experience in the pharmaceutical industry, deep scientific expertise in drug discovery and development in multiple therapeutic areas and a broad network of key relationships within the biotech and pharma industry, academia and government agencies. Before joining Foresee, Dr. Gan was President and Chief Executive Officer of the Development Center for Biotechnology (DCB) in Taipei, Taiwan. He transformed DCB, a non-profit agency, to function as an energetic pharma company and actively promoted biotech industry in Taiwan. Prior to returning to Taiwan in 2015, he served as Senior Director at Biogen, Inc., Director of Drug Discovery at Boehringer-Ingelheim, Senior Director at Millennium Pharmaceuticals, Inc., Director at the DuPont Merck Pharmaceuticals Co., and Principal Investigator at GSK. Dr. Gan participated in 5 NDA/BLA registrations and over 25 IND filings, as well as issued over eighty publications. Dr. Gan received his Ph.D. degree in Bioorganic Chemistry from Tulane University and conducted postdoctoral studies at M.I.T.
Insufficient data for Lawrence to compare compensation growth.
Insufficient data for Lawrence to establish whether their remuneration is reasonable compared to companies of similar size in Taiwan, Province of China.
Management Team Tenure
Average tenure of the
management team in years:
The tenure for the Foresee Pharmaceuticals management team is about average.
Chief Medical Officer & Representative Director
CEO & President
Co-founder & VP of RD Pipeline
Chief Financial Officer
Yang Wen Jin
Chief Scientific Officer
General Counsel & VP
Senior VP & Head of Development
Senior Vice President of NCE Preclinical & Clinical Development
Board of Directors Tenure
Average tenure of the
board of directors in years:
The tenure for the Foresee Pharmaceuticals board of directors is about average.
Board of Directors
Chief Medical Officer & Representative Director
Member of Scientific Advisory Board
Who owns this company?
Recent Insider Trading
No 3 month open market individual insider trading information.
Foresee Pharmaceuticals Co., Ltd., a clinical-stage biopharmaceutical company, engages in the development and commercialization of drugs in Taiwan and internationally. The company’s stabilized injectable formulation pipeline includes FP-001, which completed Phase III clinical study for the treatment of advanced stage prostate cancer; FP-004 that is in preclinical stage to treat substance abuse and pain relief; and FP-002 for the treatment of acromegaly and carcinoid tumors, as well as FP-008 for the treatment of diabetic retinopathy, which are products in research stage. Its new chemical entity pipeline products consists of FP-020 to treat alport syndrome; FP-025, a selective oral MMP-12 inhibitor, which is in Phase II clinical trial for inflammatory and fibrotic diseases; and FP-045, an oral molecule agonist of aldehyde dehydrogenase 2 that completed Phase I clinical study for the treatment of acute myocardial infarction, stroke, peripheral arterial disease, radiation dermatitis, Parkinson’s disease, diabetes, cancer prevention, etc. The company's strategic partners include Pierre Fabre Medicament Production and ScinoPharm. Foresee Pharmaceuticals Co., Ltd. is headquartered in Taipei, Taiwan.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.